Akhtari Mani, Reddy Jay Paul, Pinnix Chelsea C, Allen Pamela K, Osborne Eleanor M, Gunther Jillian R, Milgrom Sarah A, Smith Grace L, Wogan Christine F, Fowler Nathan, Rodriguez Maria Alma, Dabaja Bouthaina
a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
b Department of Radiation Oncology , The University of Texas Medical Branch at Galveston , Galveston , TX , USA.
Leuk Lymphoma. 2016;57(1):34-8. doi: 10.3109/10428194.2015.1040012. Epub 2015 May 12.
Primary cutaneous B cell lymphomas (PCBCL) are rare; although data on outcomes and treatment are limited, traditionally they have been treated with radiation doses in excess of 24 Gy. We retrospectively identified and reviewed all cases of PCBCL treated at our institution from 2002-2014. Thirty-nine patients with PCBCL (42 lesions) were identified. Radiation was the only treatment for most patients. All lesions had a complete response and none had in-field failures; seven patients had out-of-field relapses, three of which were salvaged with radiation therapy. No differences in PFS or OS were found for patients given low-dose (≤ 12 Gy) versus high-dose (> 12 Gy) radiation. PCBCL is an indolent entity with a long clinical course and excellent response to radiation therapy and successful salvage of recurrent disease, even when doses are as low as 4 Gy. Given the above findings, we recommend the initial use of low-dose irradiation for PCBCL.
原发性皮肤B细胞淋巴瘤(PCBCL)较为罕见;尽管关于其预后和治疗的数据有限,但传统上一直采用超过24 Gy的放射剂量进行治疗。我们回顾性地识别并审查了2002年至2014年在我们机构接受治疗的所有PCBCL病例。共识别出39例PCBCL患者(42个病灶)。放射治疗是大多数患者的唯一治疗方法。所有病灶均完全缓解,且无野内复发;7例患者出现野外复发,其中3例通过放射治疗挽救。给予低剂量(≤12 Gy)与高剂量(>12 Gy)放射治疗的患者在无进展生存期(PFS)或总生存期(OS)方面未发现差异。PCBCL是一种惰性疾病,临床病程长,对放射治疗反应良好,即使剂量低至4 Gy,复发性疾病也能成功挽救。鉴于上述发现,我们建议对PCBCL初始使用低剂量照射。